利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.022 秒)

    Corneal implant and uses thereof
    2.
    发明授权
    Corneal implant and uses thereof 失效
    角膜植入物及其用途

    公开(公告)号：US07476398B1

    公开(公告)日：2009-01-13

    申请号：US10606796

    申请日：2003-06-27

    申请人： Charles J. Doillon ,  May Griffith ,  Fengfu Li ,  Shigeto Shimmura

    发明人： Charles J. Doillon ,  May Griffith ,  Fengfu Li ,  Shigeto Shimmura

    IPC分类号： A61F2/00 ,  A61F2/14

    CPC分类号： A61F2/142 ,  A61L27/26 ,  C08L33/26

    摘要： A membrane for corneal implant or keratoprosthesis comprising a biological polymer and a polyacrylamide is described. The mixture of both polymers produces a hydrogel that becomes a transparent film or membrane upon drying. The resulting device and tissue engineered implants are useful for biomedical applications of the cornea, such as tissue repair and transplantation.

    摘要翻译： 描述了包含生物聚合物和聚丙烯酰胺的角膜植入物或角膜假体的膜。 两种聚合物的混合物产生水凝胶，其在干燥时变成透明膜或膜。 所得到的装置和组织工程植入物可用于角膜的生物医学应用，例如组织修复和移植。

    Biostable porous material comprising composite biopolymers
    3.
    发明授权
    Biostable porous material comprising composite biopolymers 失效
    生物稳定多孔材料包含复合生物聚合物

    公开(公告)号：US5863984A

    公开(公告)日：1999-01-26

    申请号：US566297

    申请日：1995-12-01

    申请人： Charles J. Doillon ,  Krystina Pietrucha ,  Rene C. Gaudreault

    发明人： Charles J. Doillon ,  Krystina Pietrucha ,  Rene C. Gaudreault

    IPC分类号： A61L27/48 ,  C08H1/06 ,  C08L89/00 ,  A61F2/00

    CPC分类号： C08H1/06 ,  A61L27/48

    摘要： Biomaterials like collagen can be designed for use as scaffolds for connective tissue reconstruction. It is known that proteins conjugated with PEGs exhibit a decrease in their biodegradation rate and their immunogenicity. Different concentrations and molecular weights of PEGs (PEG-750 and PEG-5000) were conjugated by chemical or irradiation means to collagen materials (films or sponges) which were then investigated by physicochemical assays, collagenase assay, fibroblast cell culture and subcutaneous implantation. PEG-conjugation delayed the degradation by collagenase and preserved a normal fibroblasts morphology and confluency in culture. In vivo, the porous structure of non-modified sponges was collapsed by day 15 with few observable fibroblasts between the collagen fibers. In PEG-modified collagen sponges, the porous structure remained stable for at least 30 days. Cell infiltration was particularly enhanced in PEG-750-conjugated collagen sponges. In conclusion, PEGs conjugated onto collagen sponges stabilize the porous structure without deactivating the biological properties of collagen. These porous composite materials could advantageously function as a scaffold to organize tissue ingrowth. Therefore, the present invention relates to a porous biomaterial whose porosity is stabilized by conjugation to PEG-derivatives. Biopolymers other than collagen may be used in the making of such composite materials.

    摘要翻译： 生物材料如胶原蛋白可以设计用作结缔组织重建的支架。 已知与PEG结合的蛋白质的生物降解速率及其免疫原性降低。 通过化学或照射方式将PEG（PEG-750和PEG-5000）的不同浓度和分子量缀合到胶原材料（膜或海绵）上，然后通过物理化学测定，胶原酶测定，成纤维细胞培养和皮下植入进行研究。 PEG缀合延迟了胶原酶的降解，保持了正常的成纤维细胞形态和培养中的汇合。 在体内，非修饰海绵的多孔结构在第15天塌陷，胶原纤维之间几乎没有观察到的成纤维细胞。 在PEG修饰的胶原海绵中，多孔结构保持稳定至少30天。 PEG-750缀合的胶原海绵中细胞浸润特别增强。 总之，结合到胶原海绵上的PEG稳定多孔结构，而不会使胶原蛋白的生物学性质失活。 这些多孔复合材料可以有利地用作支架以组织组织向内生长。 因此，本发明涉及一种多孔生物材料，其孔隙度通​​过与PEG衍生物缀合而稳定。 除胶原之外的生物聚合物可用于制备这种复合材料。

    Artificial cornea
    4.
    发明授权
    Artificial cornea 有权
    人造角膜

    公开(公告)号：US06645715B1

    公开(公告)日：2003-11-11

    申请号：US09624909

    申请日：2000-07-24

    申请人： May Griffith ,  Mitchell Watsky ,  Charles J. Doillon ,  Ying Song

    发明人： May Griffith ,  Mitchell Watsky ,  Charles J. Doillon ,  Ying Song

    IPC分类号： A01N102

    CPC分类号： A61L27/3804 ,  A61K35/12 ,  A61L27/3604 ,  A61L27/3641 ,  A61L27/3683 ,  A61L27/3839 ,  A61L2430/16 ,  C12N5/0621 ,  C12N2500/25 ,  C12N2500/80 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2501/392 ,  C12N2502/28 ,  C12N2502/99 ,  C12N2503/00 ,  C12N2510/04

    摘要： The invention provides an in vitro avascular human corneal equivalent that comprises immortalized human cell lines. As these corneal equivalents are in vitro models, they are maintained in an incubator throughout the testing period, thereby eliminating the problems and expense associated with animal care. The corneal equivalent is preferably surrounded by a matrix in which angiogenesis (formation of capillary-like structures) can occur in vitro. This surrounding matrix has the potential to play the role of a pseudo-sclera, allowing the in vitro assessment of the cornea's angiogenic reaction to any substance or injury. Furthermore, the model is capable of being produced easily, is physiologically functional and can give predictable and quantifiable results when submitted to various drugs, chemicals and/or physical trauma. Modifications can be made, such as the use of primary donor cells instead of cell lines; and the physical and chemical treatments of the matrix material to make the constructs suitable for use in transplantation.

    摘要翻译： 本发明提供了一种体外无血管人角膜等价物，其包含永生化的人细胞系。 由于这些角膜等效物是体外模型，它们在整个测试期间保持在培养箱中，从而消除与动物护理相关的问题和费用。 角膜等效物优选由体外可以发生血管发生（毛细血管状结构的形成）的基质包围。 这种周围的基质有潜力发挥伪巩膜的作用，允许体外评估角膜对任何物质或损伤的血管生成反应。 此外，该模型能够容易地生产，具有生理功能，并且在提交给各种药物，化学物和/或身体创伤时可以提供可预测和可量化的结果。 可以进行修改，例如使用主供体细胞代替细胞系; 以及基质材料的物理和化学处理，使构建体适用于移植。